Cancer Immunotherapy (Volume 209) (Progress in Molecular Biology and Translational Science, Volume 209). This item is unavailable.Cancer Immunotherapy (Volume 209) (Progress in Molecular Biology and Translational Science, Volume 209)

• Discusses immune surveillance of tumors and how it is compromised
• Presents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor site
• Demonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.